Comparison of dalbavancin MIC values determined by Etest (AB BIODISK) and reference dilution methods using gram-positive organisms

被引：20

作者：

Fritsche, Thomas R.

Rennie, Robert P.

Goldstein, Beth P.

Jones, Ronald N.

机构：

[1] JMI Labs, N Liberty, IA 52317 USA

[2] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada

[3] Pfizer Inc, New York, NY USA

[4] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2006年 / 44卷 / 08期

关键词：

D O I：

10.1128/JCM.00640-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

While standardized microdilution testing methodologies and quality control ranges exist for the novel glycolipopeptide dalbavancin, no testing methods have been described that are immediately available for routine use in clinical laboratories. In this study, we found that the dalbavancin Etest (AB BIODISK, Solna, Sweden) procedure demonstrated a high degree of agreement (100% within +/-2 log(2) dilution steps) with the standardized broth microdilution method, validating the use of the Etest as an alternative test for investigational or clinical purposes following regulatory approval.

引用

收藏

页码：2988 / 2990

页数：3

相关论文

共 14 条

[1] Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an Investigational glycopeptide with potent gram-positive activity [J].

Anderegg, TR ;

Biedenbach, DJ ;

Jones, RN .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (06) :2795-2796

[2]

Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA

[3] Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections [J].

Ellis, MW ;

Lewis, JS .

CURRENT OPINION IN INFECTIOUS DISEASES, 2005, 18 (06) :496-501

[4] Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections [J].

Jauregui, LE ;

Babazadeh, S ;

Seltzer, E ;

Goldberg, L ;

Krievins, D ;

Frederick, M ;

Krause, D ;

Satilovs, I ;

Endzinas, Z ;

Breaux, J ;

O'Riordan, W .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (10) :1407-1415

[5] Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004) [J].

Jones, RN ;

Stilwell, MG ;

Sader, HS ;

Fritsche, TR ;

Goldstein, BP .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (02) :149-153

[6] Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and north America (2003): Initial results from an international surveillance protocol [J].

Jones, RN ;

Fritsche, TR ;

Sader, HS ;

Goldstein, BP .

JOURNAL OF CHEMOTHERAPY, 2005, 17 (06) :593-600

[7] Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide [J].

Jones, RN ;

Streit, JM ;

Fritsche, TR .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) :197-199

[8] Antistaphylococcal activity of dalbavancin, an experimental glycopeptide [J].

Lin, G ;

Credito, K ;

Ednie, LM ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (02) :770-772

[9] Origin, structure, and activity in vitro and in vivo of dalbavancin [J].

Malabarba, A ;

Goldstein, BP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 :15-20

[10] Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods [J].

Mushtaq, S ;

Warner, M ;

Johnson, AP ;

Livermore, DM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (03) :617-620